Shopping Cart 0
Cart Subtotal
AED 0

Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 19708

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 33012

Details

According to a new report published by Allied Market Research, titled,"Intravenous Immunoglobulin (IVIG) Market by Application and Type: Global Opportunity Analysis and Industry Forecast, 2018-2025,"the global intravenous immunoglobulin market accounted for USD 8,995 million in 2017, and is projected to reach USD 15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.

Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds its application in various fields, including hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. The prevalence of a host of antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, & hypogammaglobulinemia; increase in immunoglobulin indications; improved production & purification processes; growth in awareness toward antibody deficiency; and rare immune disorders among patient population drive the growth of the global intravenous immunoglobulin market.

Based on application segment, hypogammaglobulinemia held the largest market share in 2017, and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.

Key Findings of the Intravenous Immunoglobulin (IVIG) Market:

Myasthenia gravis segment is projected to grow at the highest rate during the forecast period.

Hypogammaglobulinemia was the largest revenue contributor in 2017 and is expected to continue its dominance throughout the forecast period.

North America dominated the global intravenous immunoglobulin market in 2017.

LAMEA is estimated to grow at the highest CAGR of 10.3% from 2018-2025.

In 2017, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the intravenous market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. coupled with the presence of large plasma production facilities.

The key companies profiled in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer AG. The other players included in the value chain analysis (but not included in the report) are Omrix Biopharmaceuticals Ltd.; Behring GmbH; Shanghai RAAS Blood Products Co., Ltd.; Option Care Enterprises, Inc.; ADMA Biologics, Inc.; and BioScrip, Inc.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

READ MORE

Table Of Content

Scope

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Overview of Immunoglobulin

3.2.1. Patented products

3.2.2. Epidemiology and economic burden of chronic conditions

3.3. Key findings

3.3.1. Top Investment Pockets

3.4. Porters five forces analysis

3.5. Value chain analysis

3.5.1. Primary activities

3.5.2. Support activities

3.6. Market share analysis, 2017

3.7. Product scenario in intravenous immunoglobulin market

3.8. Government regulations and reimbursements

3.8.1. U.S.

3.8.2. Europe

3.8.3. France

3.8.4. Germany

3.8.5. Italy

3.8.6. China

3.8.7. Japan

3.8.8. India

3.9. Indications for immunoglobulin

3.9.1. U.S. FDA indications

3.9.2. EMA

3.10. Component analysis of immunoglobulin G (IgG)

3.10.1. IgG1

3.10.2. IgG2

3.10.3. IgG3

3.10.4. IgG4

3.11. Market dynamics

3.11.1. Drivers

3.11.1.1. Rise in prevalence of immunodeficiency diseases

3.11.1.2. Increase in adoption of immunoglobulin treatment

3.11.1.3. Growth in incidence of bleeding disorders

3.11.2. Restraints

3.11.2.1. Stringent government regulations

3.11.2.2. High cost of therapy

3.11.3. Opportunities

3.11.3.1. Opportunities in emerging economies

3.11.3.2. Development of cost-effective therapeutics through large-scale production

CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Hypogammaglobulinemia

4.2.1. Market size and forecast

4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1. Market size and forecast

4.4. Primary immunodeficiency diseases

4.4.1. Market size and forecast

4.5. Myasthenia Gravis

4.5.1. Market size and forecast

4.6. Multifocal motor neuropathy

4.6.1. Market size and forecast

4.7. Idiopathic thrombocytopenic purpura (ITP)

4.7.1. Market size and forecast

4.8. Inflammatory myopathies

4.8.1. Market size and forecast

4.9. Specific antibody deficiency

4.9.1. Market size and forecast

4.10. Guillain-Barre syndrome

4.10.1. Market size and forecast

4.11. Others

4.11.1. Market size and forecast

CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. Overview

5.1.1. IGG

5.1.1.1. Key market trends

5.1.2. Clinical interpretations

5.1.3. IGA

5.1.3.1. Key Market Trends

5.1.4. Clinical interpretation

5.1.5. IGM

5.1.5.1. Key Market Trends

5.1.6. Clinical interpretation

5.1.7. IGE

5.1.7.1. Key Market Trend

5.1.8. Clinical interpretation

5.1.9. IGD

5.1.9.1. Key Market Trends

5.1.10. Clinical interpretation

CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key trends and opportunities

6.2.2. North America market size & forecast, by application

6.2.3. North America market size & forecast, by country

6.2.3.1. U.S. market size & forecast

6.2.3.2. Canada market size & forecast

6.2.3.3. Mexico market size & forecast

6.3. Europe

6.3.1. Key trends and opportunities

6.3.2. Europe market size & forecast, by application

6.3.3. Europe market size & forecast for immunoglobulin market, by country

6.3.3.1. Germany market size & forecast

6.3.3.2. France market size & forecast

6.3.3.3. UK market size & forecast

6.3.3.4. Italy market size & forecast

6.3.3.5. Austria market size & forecast

6.3.3.6. Russia market size & forecast

6.3.3.7. Rest of Europe market size & forecast

6.4. Asia-Pacific

6.4.1. Key trends and opportunities

6.4.2. Asia-Pacific market size & forecast, by application

6.4.3. Asia-Pacific market size & forecast, by country

6.4.3.1. Australia market size & forecast

6.4.3.2. China market size & forecast

6.4.3.3. India market size & forecast

6.4.3.4. Japan market size & forecast

6.4.3.5. Rest of Asia-Pacific market size & forecast

6.5. LAMEA

6.5.1. Key trends and opportunities

6.5.2. LAMEA market size & forecast, by application

6.5.3. LAMEA market size & forecast, by country

6.5.3.1. Brazil market size & forecast

6.5.3.2. Saudi Arabia market size & forecast

6.5.3.3. Argentina market size & forecast

6.5.3.4. Turkey market size & forecast

6.5.3.5. Rest of LAMEA market size & forecast

CHAPTER 7: COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC.

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product portfolio

7.1.5. Business performance

7.1.6. Key strategic moves and developments

7.2. BAYER AG

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

7.3. BIOTEST AG

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product portfolio

7.3.5. Business performance

7.4. CHINA BIOLOGIC PRODUCTS, INC.

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

7.5. CSL LIMITED

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product portfolio

7.5.5. Business performance

7.6. GRIFOLS S.A.

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

7.7. KEDRION BIOPHARMA INC.

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product portfolio

7.7.5. Business performance

7.7.6. Key strategic moves and developments

7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product portfolio

7.8.5. Business performance

7.9. OCTAPHARMA AG

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product portfolio

7.9.5. Business performance

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product portfolio

7.10.5. Business performance

7.10.6. Key strategic moves and developments


List Of Figure

LIST OF FIGURES

FIGURE 01. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 04. LOW BARGAINING POWER OF BUYERS

FIGURE 05. LOW THREAT OF SUBSTITUTION

FIGURE 06. LOW THREAT OF NEW ENTRANTS

FIGURE 07. MODERTAE COMPETITIVE RIVALRY

FIGURE 08. VALUE CHAIN ANALYSIS

FIGURE 09. MARKET SHARE ANALYSIS, 2017

FIGURE 10. GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES

FIGURE 11. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 12. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 13. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 14. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 15. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 16. UK INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 17. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 18. AUSTRIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 19. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

REST OF EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 20. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 21. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 22. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 23. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 24. REST OF ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 25. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 26. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 27. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 28. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 29. REST OF LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 30. BAXTER: NET SALES, 20152017 (USD MILLION)

FIGURE 31. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 32. BAYER: NET SALES, 20152017 (USD MILLION)

FIGURE 33. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 34. BAYER: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 35. BIOTEST: NET SALES, 20152017 (USD MILLION)

FIGURE 36. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 37. BIOTEST: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 38. CHINA BIOLOGIC NET SALES, 20152017 (USD MILLION)

FIGURE 39. CSL: NET SALES, 20152017 (USD MILLION)

FIGURE 40. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 41. CSL: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 42. GRIFOLS: NET SALES, 20152017 (USD MILLION)

FIGURE 43. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 44. GRIFOLS: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 45. KEDRION: NET SALES, 20152017 (USD MILLION)

FIGURE 46. KEDRION: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 47. LFB: NET SALES, 20142016 (USD MILLION)

FIGURE 48. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)

FIGURE 49. LFB: REVENUE SHARE BY REGION, 2016 (%)

FIGURE 50. OCTAPHARMA: NET SALES, 20152017 (USD MILLION)

FIGURE 51. TAKEDA: NET SALES, 20152017 (USD MILLION)

FIGURE 52. TAKEDA: REVENUE SHARE BY REGION, 2017 (%)


List Of Table

LIST OF TABLES

TABLE 01. COMMERCIALIZED IMMUNOGLOBULIN PRODUCTS

TABLE 02. U.S. FDA INDICATIONS FOR IMMUNOGLOBULIN

TABLE 03. EMA-APPROVED INDICATIONS FOR IMMUNOGLOBULIN

TABLE 04. IGG SUBCLASS

TABLE 05. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS

TABLE 06. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY

TABLE 07. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 08. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAM)

TABLE 09. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS

TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 (USD MILLION)

TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 (KILOGRAMS)

TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIDP, BY REGION, 20172025 (USD MILLION)

TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 (KILOGRAMS)

TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 20172025 (USD MILLION)

TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 20172025 (KILOGRAMS)

TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (USD MILLION)

TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (KILOGRAMS)

TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (USD MILLION)

TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (KILOGRAMS)

TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (USD MILLION)

TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (KILOGRAMS)

TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (USD MILLION)

TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (KILOGRAMS)

TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (USD MILLION)

TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (KILOGRAMS)

TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 20172025 (USD MILLION)

TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION, 20172025 (KILOGRAMS)

TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (USD MILLION)

TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (KILOGRAMS)

TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 20172025 (USD MILLION)

TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 2017-2025 (KILOGRAMS))

TABLE 32. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 33. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 34. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 35. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 36. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 37. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 38. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 39. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 40. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 41. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 42. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

TABLE 43. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 44. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 45. LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 46. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 47. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 48. BAXTER: COMPANY SNAPSHOT

TABLE 49. BAXTER: OPERATING SEGMENTS

TABLE 50. BAXTER: PRODUCT PORTFOLIO

TABLE 51. BAYER: COMPANY SNAPSHOT

TABLE 52. BAYER: OPERATING SEGMENTS

TABLE 53. BAXTER: PRODUCT PORTFOLIO

TABLE 54. BIOTEST: COMPANY SNAPSHOT

TABLE 55. BIOTEST: OPERATING SEGMENTS

TABLE 56. BIOTEST: OPERATING SEGMENT

TABLE 57. CHINA BIOLOGIC COMPANY SNAPSHOT

TABLE 58. CHINA BIOLOGIC PRODUCT PORTFOLIO

TABLE 59. CSL: COMPANY SNAPSHOT

TABLE 60. CSL: PRODUCT SEGMENTS

TABLE 61. CSL: PRODUCT PORTFOLIO

TABLE 62. GRIFOLS: COMPANY SNAPSHOT

TABLE 63. GRIFOLS: OPERATING SEGMENTS

TABLE 64. GRIFOLS: PRODUCT PORTFOLIO

TABLE 65. KEDRION: COMPANY SNAPSHOT

TABLE 66. KEDRION: PRODUCT PORTFOLIO

TABLE 67. LFB: COMPANY SNAPSHOT

TABLE 68. LFB: PRODUCT SEGMENTS

TABLE 69. LFB: PRODUCT PORTFOLIO

TABLE 70. OCTAPHARMA: COMPANY SNAPSHOT

TABLE 71. OCTAPHARMA: PRODUCT SEGMENTS

TABLE 72. OCTAPHARMA: PRODUCT PORTFOLIO

TABLE 73. TAKEDA: COMPANY SNAPSHOT

TABLE 74. TAKEDA: PRODUCT PORTFOLIO

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

According to a new report published by Allied Market Research, titled,"Intravenous Immunoglobulin (IVIG) Market by Application and Type: Global Opportunity Analysis and Industry Forecast, 2018-2025,"the global intravenous immunoglobulin market accounted for USD 8,995 million in 2017, and is projected to reach USD 15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.

Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds its application in various fields, including hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. The prevalence of a host of antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, & hypogammaglobulinemia; increase in immunoglobulin indications; improved production & purification processes; growth in awareness toward antibody deficiency; and rare immune disorders among patient population drive the growth of the global intravenous immunoglobulin market.

Based on application segment, hypogammaglobulinemia held the largest market share in 2017, and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.

Key Findings of the Intravenous Immunoglobulin (IVIG) Market:

Myasthenia gravis segment is projected to grow at the highest rate during the forecast period.

Hypogammaglobulinemia was the largest revenue contributor in 2017 and is expected to continue its dominance throughout the forecast period.

North America dominated the global intravenous immunoglobulin market in 2017.

LAMEA is estimated to grow at the highest CAGR of 10.3% from 2018-2025.

In 2017, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the intravenous market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. coupled with the presence of large plasma production facilities.

The key companies profiled in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer AG. The other players included in the value chain analysis (but not included in the report) are Omrix Biopharmaceuticals Ltd.; Behring GmbH; Shanghai RAAS Blood Products Co., Ltd.; Option Care Enterprises, Inc.; ADMA Biologics, Inc.; and BioScrip, Inc.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

READ MORE

Scope

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Overview of Immunoglobulin

3.2.1. Patented products

3.2.2. Epidemiology and economic burden of chronic conditions

3.3. Key findings

3.3.1. Top Investment Pockets

3.4. Porters five forces analysis

3.5. Value chain analysis

3.5.1. Primary activities

3.5.2. Support activities

3.6. Market share analysis, 2017

3.7. Product scenario in intravenous immunoglobulin market

3.8. Government regulations and reimbursements

3.8.1. U.S.

3.8.2. Europe

3.8.3. France

3.8.4. Germany

3.8.5. Italy

3.8.6. China

3.8.7. Japan

3.8.8. India

3.9. Indications for immunoglobulin

3.9.1. U.S. FDA indications

3.9.2. EMA

3.10. Component analysis of immunoglobulin G (IgG)

3.10.1. IgG1

3.10.2. IgG2

3.10.3. IgG3

3.10.4. IgG4

3.11. Market dynamics

3.11.1. Drivers

3.11.1.1. Rise in prevalence of immunodeficiency diseases

3.11.1.2. Increase in adoption of immunoglobulin treatment

3.11.1.3. Growth in incidence of bleeding disorders

3.11.2. Restraints

3.11.2.1. Stringent government regulations

3.11.2.2. High cost of therapy

3.11.3. Opportunities

3.11.3.1. Opportunities in emerging economies

3.11.3.2. Development of cost-effective therapeutics through large-scale production

CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Hypogammaglobulinemia

4.2.1. Market size and forecast

4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1. Market size and forecast

4.4. Primary immunodeficiency diseases

4.4.1. Market size and forecast

4.5. Myasthenia Gravis

4.5.1. Market size and forecast

4.6. Multifocal motor neuropathy

4.6.1. Market size and forecast

4.7. Idiopathic thrombocytopenic purpura (ITP)

4.7.1. Market size and forecast

4.8. Inflammatory myopathies

4.8.1. Market size and forecast

4.9. Specific antibody deficiency

4.9.1. Market size and forecast

4.10. Guillain-Barre syndrome

4.10.1. Market size and forecast

4.11. Others

4.11.1. Market size and forecast

CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. Overview

5.1.1. IGG

5.1.1.1. Key market trends

5.1.2. Clinical interpretations

5.1.3. IGA

5.1.3.1. Key Market Trends

5.1.4. Clinical interpretation

5.1.5. IGM

5.1.5.1. Key Market Trends

5.1.6. Clinical interpretation

5.1.7. IGE

5.1.7.1. Key Market Trend

5.1.8. Clinical interpretation

5.1.9. IGD

5.1.9.1. Key Market Trends

5.1.10. Clinical interpretation

CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key trends and opportunities

6.2.2. North America market size & forecast, by application

6.2.3. North America market size & forecast, by country

6.2.3.1. U.S. market size & forecast

6.2.3.2. Canada market size & forecast

6.2.3.3. Mexico market size & forecast

6.3. Europe

6.3.1. Key trends and opportunities

6.3.2. Europe market size & forecast, by application

6.3.3. Europe market size & forecast for immunoglobulin market, by country

6.3.3.1. Germany market size & forecast

6.3.3.2. France market size & forecast

6.3.3.3. UK market size & forecast

6.3.3.4. Italy market size & forecast

6.3.3.5. Austria market size & forecast

6.3.3.6. Russia market size & forecast

6.3.3.7. Rest of Europe market size & forecast

6.4. Asia-Pacific

6.4.1. Key trends and opportunities

6.4.2. Asia-Pacific market size & forecast, by application

6.4.3. Asia-Pacific market size & forecast, by country

6.4.3.1. Australia market size & forecast

6.4.3.2. China market size & forecast

6.4.3.3. India market size & forecast

6.4.3.4. Japan market size & forecast

6.4.3.5. Rest of Asia-Pacific market size & forecast

6.5. LAMEA

6.5.1. Key trends and opportunities

6.5.2. LAMEA market size & forecast, by application

6.5.3. LAMEA market size & forecast, by country

6.5.3.1. Brazil market size & forecast

6.5.3.2. Saudi Arabia market size & forecast

6.5.3.3. Argentina market size & forecast

6.5.3.4. Turkey market size & forecast

6.5.3.5. Rest of LAMEA market size & forecast

CHAPTER 7: COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC.

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product portfolio

7.1.5. Business performance

7.1.6. Key strategic moves and developments

7.2. BAYER AG

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

7.3. BIOTEST AG

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product portfolio

7.3.5. Business performance

7.4. CHINA BIOLOGIC PRODUCTS, INC.

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

7.5. CSL LIMITED

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product portfolio

7.5.5. Business performance

7.6. GRIFOLS S.A.

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

7.7. KEDRION BIOPHARMA INC.

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product portfolio

7.7.5. Business performance

7.7.6. Key strategic moves and developments

7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product portfolio

7.8.5. Business performance

7.9. OCTAPHARMA AG

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product portfolio

7.9.5. Business performance

7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product portfolio

7.10.5. Business performance

7.10.6. Key strategic moves and developments


List Of Figure

LIST OF FIGURES

FIGURE 01. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 04. LOW BARGAINING POWER OF BUYERS

FIGURE 05. LOW THREAT OF SUBSTITUTION

FIGURE 06. LOW THREAT OF NEW ENTRANTS

FIGURE 07. MODERTAE COMPETITIVE RIVALRY

FIGURE 08. VALUE CHAIN ANALYSIS

FIGURE 09. MARKET SHARE ANALYSIS, 2017

FIGURE 10. GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES

FIGURE 11. U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 12. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 13. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 14. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 15. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 16. UK INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 17. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 18. AUSTRIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 19. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

REST OF EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 20. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 21. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 22. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 23. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 24. REST OF ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 25. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 26. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 27. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 28. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 29. REST OF LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

FIGURE 30. BAXTER: NET SALES, 20152017 (USD MILLION)

FIGURE 31. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 32. BAYER: NET SALES, 20152017 (USD MILLION)

FIGURE 33. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 34. BAYER: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 35. BIOTEST: NET SALES, 20152017 (USD MILLION)

FIGURE 36. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 37. BIOTEST: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 38. CHINA BIOLOGIC NET SALES, 20152017 (USD MILLION)

FIGURE 39. CSL: NET SALES, 20152017 (USD MILLION)

FIGURE 40. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 41. CSL: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 42. GRIFOLS: NET SALES, 20152017 (USD MILLION)

FIGURE 43. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 44. GRIFOLS: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 45. KEDRION: NET SALES, 20152017 (USD MILLION)

FIGURE 46. KEDRION: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 47. LFB: NET SALES, 20142016 (USD MILLION)

FIGURE 48. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)

FIGURE 49. LFB: REVENUE SHARE BY REGION, 2016 (%)

FIGURE 50. OCTAPHARMA: NET SALES, 20152017 (USD MILLION)

FIGURE 51. TAKEDA: NET SALES, 20152017 (USD MILLION)

FIGURE 52. TAKEDA: REVENUE SHARE BY REGION, 2017 (%)


List Of Table

LIST OF TABLES

TABLE 01. COMMERCIALIZED IMMUNOGLOBULIN PRODUCTS

TABLE 02. U.S. FDA INDICATIONS FOR IMMUNOGLOBULIN

TABLE 03. EMA-APPROVED INDICATIONS FOR IMMUNOGLOBULIN

TABLE 04. IGG SUBCLASS

TABLE 05. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS

TABLE 06. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY

TABLE 07. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 08. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAM)

TABLE 09. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS

TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 (USD MILLION)

TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 (KILOGRAMS)

TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIDP, BY REGION, 20172025 (USD MILLION)

TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 (KILOGRAMS)

TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 20172025 (USD MILLION)

TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR PRIMARY IMMUNODEFICIENCY DISEASES BY REGION, 20172025 (KILOGRAMS)

TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (USD MILLION)

TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (KILOGRAMS)

TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (USD MILLION)

TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (KILOGRAMS)

TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (USD MILLION)

TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (KILOGRAMS)

TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (USD MILLION)

TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (KILOGRAMS)

TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (USD MILLION)

TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (KILOGRAMS)

TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 20172025 (USD MILLION)

TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION, 20172025 (KILOGRAMS)

TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (USD MILLION)

TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (KILOGRAMS)

TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 20172025 (USD MILLION)

TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, 2017-2025 (KILOGRAMS))

TABLE 32. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 33. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 34. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 35. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 36. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 37. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 38. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 39. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 40. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 41. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 42. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, VALUE (USD MILLION) AND VOLUME (KILOGRAMS), 2017-2025

TABLE 43. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 44. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (USD MILLION)

TABLE 45. LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAMS)

TABLE 46. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (USD MILLION)

TABLE 47. LAMEA INTRAVENOUS IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)

TABLE 48. BAXTER: COMPANY SNAPSHOT

TABLE 49. BAXTER: OPERATING SEGMENTS

TABLE 50. BAXTER: PRODUCT PORTFOLIO

TABLE 51. BAYER: COMPANY SNAPSHOT

TABLE 52. BAYER: OPERATING SEGMENTS

TABLE 53. BAXTER: PRODUCT PORTFOLIO

TABLE 54. BIOTEST: COMPANY SNAPSHOT

TABLE 55. BIOTEST: OPERATING SEGMENTS

TABLE 56. BIOTEST: OPERATING SEGMENT

TABLE 57. CHINA BIOLOGIC COMPANY SNAPSHOT

TABLE 58. CHINA BIOLOGIC PRODUCT PORTFOLIO

TABLE 59. CSL: COMPANY SNAPSHOT

TABLE 60. CSL: PRODUCT SEGMENTS

TABLE 61. CSL: PRODUCT PORTFOLIO

TABLE 62. GRIFOLS: COMPANY SNAPSHOT

TABLE 63. GRIFOLS: OPERATING SEGMENTS

TABLE 64. GRIFOLS: PRODUCT PORTFOLIO

TABLE 65. KEDRION: COMPANY SNAPSHOT

TABLE 66. KEDRION: PRODUCT PORTFOLIO

TABLE 67. LFB: COMPANY SNAPSHOT

TABLE 68. LFB: PRODUCT SEGMENTS

TABLE 69. LFB: PRODUCT PORTFOLIO

TABLE 70. OCTAPHARMA: COMPANY SNAPSHOT

TABLE 71. OCTAPHARMA: PRODUCT SEGMENTS

TABLE 72. OCTAPHARMA: PRODUCT PORTFOLIO

TABLE 73. TAKEDA: COMPANY SNAPSHOT

TABLE 74. TAKEDA: PRODUCT PORTFOLIO

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS